Pierre Fabre Medicament

Centre National De La Recherche Scientifique

Institut National De La Recherche Agronomique

Université Paul Sabatier (toulouse Iii)

Institut National Des Sciences Appliquees Toulouse

Institut National Des Sciences Appliquees De Toulouse

Etienne Severac

Alain Marty

André Delhon

Frédérique Brune

Jean Gardette

Jean François Patoiseau

Magali Remaud-Simeon

Pierre Monsan

Claire Moulis

Marlène Vuillemin

Marion Claverie

Catherine Fontagne-Faucher

The invention relates to: &#x2014;a protein having dextran-saccharase activity and the sequence SEQ ID NO: 1 for an amino acid sequence; &#x2014;a protein having dextran-saccharase activity and the sequence SEQ ID NO: 2 for an amino acid sequence; &#x2014;a complex containing a substrate and a protein with dextran-saccharase activity &#x2014;a method for synthesizing dextrans; and &#x2014;dextrans. The invention also relates to a method for synthesizing gluco-oligosaccharides and gluco-conjugates and to the resulting products.

Protein with dextran-saccharase activity, and uses

The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. 

DHA esters and use thereof in treatment and prevention of cardiovascular disease

The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.

Growing community of inventors

Pibrac, France

Etienne Severac